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Abstract
Protein microarrays are potentially powerful tools in biochem-
istry and molecular biology. Two types of protein microarrays are
defined. One, termed a protein function array, will consist of
thousands of native proteins immobilized in a defined pattern.
Such arrays can be utilized for massively parallel testing of protein
function, hence the name. The other type is termed a protein-
detecting array. This will consist of large numbers of arrayed
protein-binding agents. These arrays will allow for expression
profiling to be done at the protein level. In this article, some of the
major technological challenges to the development of protein
arrays are discussed, along with potential solutions. ß 2001
Elsevier Science Ltd. All rights reserved.
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1. Introduction
Nowhere is the frenetic pace of biological research more
apparent than in the genomics/proteomics area. Only this
summer, the human genome sequence was (mostly) com-
pleted, an event that many compared in signi¢cance to
landing a man on the moon. Yet almost before the ink
on the Time magazine cover was dry, it seemed that most
of the discussion had already turned to the next huge
challenge: building on this wealth of DNA sequence in-
formation to ‘solve’ the human proteome. Most biochem-
ists would de¢ne this formidable undertaking as character-
izing every protein encoded by the human genome. This
would include understanding its function, structure, mo-
lecular interactions and regulation in various cell types. It
is likely that chemical biologists can make major contri-
butions to this area.
In order to tackle a problem of this magnitude, it is
clear to everyone that new techniques capable of very
high throughput will be required. High on this wish list
are so-called protein chips or protein microarrays, of
which there are two types. I would like to propose a no-
menclature to distinguish these, since their applications
and the challenges involved in constructing them are
very di¡erent. One is an array in which each protein in
a cell occupies a de¢ned spot on the chip. I will refer to
these as protein function arrays since such devices would
be employed for highly parallel studies of the activities of
native proteins. For example, if one wished to know all
proteins associated with some protein X, then a £uores-
cently labeled protein X derivative might be incubated
with a protein function microarray. Spots that ‘light up’
would be considered excellent candidates for protein X
binding partners (Fig. 1). The second type of chip is
more correctly called a protein-detecting array. In this
case, rather than spotting down the native proteins them-
selves, one would array highly speci¢c ligands to each
protein capable of recognizing their target polypeptide in
complex biological solutions, such as a cell extract. This
type of chip would serve as an analytical tool somewhat
analogous to DNA microarrays in the sense that it would
be capable of monitoring protein levels in a given biolog-
ical sample in a massively parallel fashion (Fig. 1). In
other words, protein-detecting arrays would be to the
Western blot what DNA microarrays are to the Northern
blot. The potential impact of protein-detecting chips ex-
tends far beyond basic research. It seems likely that if this
technology could be made practical, it might form the
backbone of 21st century medical diagnostics. Given the
huge potential market for such devices, industrial interest
in protein-detecting chips is very high.
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This article reviews progress in this very young ¢eld and
discusses some of the challenges that must be surmounted
to achieve practically useful devices. Before beginning, it is
important to admit that there is undoubtedly important
but unpublished work going on of which I am unaware,
particularly in the biotechnology industry. Thus, this dis-
cussion should not be considered a comprehensive review
of this rapidly expanding area.
2. Why do we need protein function and protein-detecting
arrays?
Whenever one wishes to develop new methodology,
whether in organic synthesis, molecular biology or pro-
teomics, it is critical to ¢rst address the limitations and
problems of existing related technology and to focus new
e¡orts on addressing these issues. The 800 lb gorilla in the
high-throughput genomics area is the DNA microarray,
which has revolutionized many areas of biology [1].
DNA microarrays are chemically modi¢ed glass slides
onto which have been placed large numbers of di¡erent
DNAs that are complementary to nucleic acids of interest,
for example genes. Depending on the type of array, these
DNAs are oligonucleotides synthesized on the chip by
photolithographic methods [2], or polymerase chain reac-
tion (PCR) products spotted onto the chip by a robot [3].
The application of DNA microarrays most relevant to this
article is to monitor the e¡ect of a given stimulus or ge-
netic alteration on the expression of thousands of genes
simultaneously (genome-wide expression analysis). With-
out going into technical details, the basic protocol is to
isolate total mRNA from the sample of interest and to
make cDNA by reverse transcription (RT). Fluorescent
labels are incorporated during this process, allowing later
visualization of the DNA. The sample is then hybridized
to the DNA microarray under conditions where there is
far more immobilized probe than DNA analyte. Thus, the
intensity of the £uorescence that hybridizes to each spot
re£ects the amount of each mRNA molecule in the orig-
inal sample. By comparing data obtained from two di¡er-
ent samples, for example wild-type yeast and a congenic
deletion mutant, or cells that were or were not treated with
a given drug, illuminating insights can be obtained regard-
ing global e¡ects of these variables on cellular metabolism.
One of the more striking applications of this technology
has been the discovery of gene expression patterns char-
acteristic of a disease state, such as cancer [4,5].
As useful as DNA microarrays are, they have several
limitations. Of course, what one would really like to know
is how a genetic alteration, drug, or change in the environ-
ment e¡ects protein levels and activities. mRNA-based
measurements provide only an indirect measure. The ex-
pression levels of many genes are subject to signi¢cant
post-transcriptional regulation, meaning that the message
levels do not always re£ect protein levels accurately.
Sometimes this discrepancy can be 20-fold or larger [6].
Even more important is that the activities of many pro-
teins are grossly a¡ected by post-translational modi¢ca-
tions such as phosphorylation, glycosylation, acetylation,
proteolysis, etc. Obviously, a nucleic acid-based array is
blind to such e¡ects. Finally, for certain applications, the
tedious sample preparation requirements of DNA micro-
arrays make them impractical. For example, because of
heightened concern over bioterrorism, the US Department
of Defense is very interested in developing new technolo-
gies with which to detect pathogen infections. In theory,
Fig. 1. Schematic representation of the two major classes of protein ar-
rays. Top: Protein function arrays. Native proteins (colored orange) will
be obtained from cDNAs by in vitro transcription/translation or some
other technique, then spotted down onto a suitable surface. These ar-
rays will be used to probe the function or binding properties of native
proteins. In the example shown, the array is sampled for those factors
that bind directly to a particular protein X, that is labeled with a green
dye such as £uorescein. The spots that ‘light up’ are candidate binding
partners. Bottom: Protein-detecting arrays. In this case, the native pro-
teins are used as targets for library screening experiments. One of more
ligands (shown in blue) that bind with high a⁄nity and speci¢city to
each protein will be obtained. These protein ligands will then be arrayed
on the appropriate surface. These chips will be used for proteome pro¢l-
ing. In the example shown, all of the proteins in two biological samples
that one would like to compare are labeled with distinguishable markers
(here represented as red or green colors). The mixed samples are then
incubated with the array. Spots that show up as green or red have an
excess of protein from one sample over the other. Spots that appear
brown are meant to represent a rough equivalence of the amount of
proteins from each sample. This type of experiment, analogous to gene
expression pro¢ling with DNA microarrays, would allow the e¡ect of
various physiological stimuli or genetic alterations on proteins levels to
be examined.
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DNA microarrays could be very useful for this purpose,
since even an early stage, pre-clinical pathogen infection
would probably produce a diagnostic signature pattern of
gene expression in certain cells. However, for this kind of
real world application to be practical, thousands of indi-
viduals would have to be tested rapidly using readily ob-
tained and minimally processed samples. Thus, the RT/
£uorescent labeling technology required in current DNA
microarray technology makes it a non-starter for the mili-
tary. One can imagine that similar issues, but based on
cost rather than speed and convenience, might limit the
general use of DNA microarrays in civilian medical diag-
nostics.
The solution, of course, is to analyze proteins directly,
rather than make inferences based on RNA levels. This is
perhaps the key goal in the new area of proteomics. Pro-
teomics technology is currently dominated by two-dimen-
sional (2D) gel electrophoresis/mass spectrometry (MS)-
based methods [7]. In this approach, the proteome of in-
terest is resolved as much as possible into discrete protein
spots using 2D electrophoresis and then the identity of the
protein(s) in each spot is identi¢ed by MS or MS/MS.
While useful for certain applications, this technique is
very limited in scope. MS is an excellent detection tool,
but cannot easily be used quantitatively, though novel
strategies are being developed to circumvent this problem
(vide infra). The real limitation here though is the 2D
electrophoresis technique. Obviously, this tedious process
cannot support the high-throughput required of real world
medical diagnostics. Even more seriously, careful recent
studies have shown that low abundance proteins are not
easily detected in silver-stained 2D gels. For example, a
study using yeast extracts concluded that almost half of
the proteome was invisible using 2D electrophoresis/MS
proteomics [8]. This is unfortunate, since it is often the
less highly expressed proteins that respond in the most
interesting way to various physiological stimuli. Therefore,
while 2D electrophoresis/MS-based methods will probably
continue to be the workhorse in the ¢eld for the next
couple of years, the need to move beyond this technology
is clear.
The above discussion was mostly relevant to protein-
detecting arrays. Why do we need protein function arrays?
The aforementioned example of detecting all binding part-
ners of a given protein X is a good place to start. Most
investigators would employ one of two techniques for this
purpose, either a two-hybrid experiment [9,10] or protein
a⁄nity chromatography [11]. The former is extremely use-
ful, but su¡ers from the fact that the proteins of interest
must be employed as part of arti¢cial fusion proteins. This
means that binding assays in which one wishes to employ
a multi-protein complex, for example, cannot be carried
out using this method. In addition, proteins that do not
express well in yeast or which are transcriptional activa-
tors cannot be employed as bait in this assay. Perhaps
most importantly, the control of the experimenter over
the conditions employed in an in vivo assay is very limited,
while in a protein function array-based experiment, the
conditions could be adjusted as desired. The array-based
method is distinguished from a⁄nity chromatography in
that it would only detect direct binding events. A unique
application of protein function arrays would be to inves-
tigate small molecule^protein interactions on a proteome-
wide scale, for which there are not many good methods
[12]. This type of application is relevant to a problem
frequently encountered in the pharmaceutical industry,
which is whether a given drug candidate binds tightly to
any proteins other than its intended target. This sort of
analysis would be relatively straightforward using a pro-
tein function array and a labeled drug candidate.
Fig. 2. Example of a model protein function microarray and its use in
probing protein^protein interactions. Protein G, p50 and the FKBP-ra-
pamycin binding (FRB) domain of FRAP were spotted onto a chemi-
cally derivatized glass slide, four spots each. The slide was then probed
with various £uorescently labeled proteins. (A) Slide probed with BODI-
PY-FL-IgG, known to bind protein G. (B) Slide probed with Cy3-la-
beled IkBa, known to bind to p50. (C) Slide probed with Cy5-labeled
FKBP12, known to bind FRB in the presence of rapamycin. In this ex-
periment rapamycin was included in the bu¡er. (D) Same as (C), except
rapamycin was not present. (E) Slide probed with all three labeled pro-
teins in the presence of rapamycin. BODIPY-FL, Cy3 and Cy5 £uores-
cence were false-colored blue, green and red, respectively. Reprinted
with permission from [13].
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3. Near-term prospects for protein function arrays
The construction and use of protein function arrays is a
much simpler problem than the development of practically
useful protein-detecting arrays. Indeed, signi¢cant prog-
ress has recently been reported in the former area. Mac-
Beath and Schreiber have described the immobilization
chemistry and robotics necessary to make high-density
protein function arrays [13]. They also reported model
experiments that indicate that these arrays should indeed
be useful for the sort of binding experiments discussed
above (Fig. 2). The main issue in moving from this dem-
onstration of feasibility to real protein function arrays will
be to produce the thousands of proteins to be spotted
down onto the slide. For complete protein function arrays
(i.e. covering the entire proteome), it is probably imprac-
tical to do this by standard methods of expression of
tagged recombinant proteins in Escherichia coli or Sf9 cells
followed by a⁄nity puri¢cation, though for modest-sized
arrays this would be reasonable (also see [14] for a pool-
based method using glutathione S-transferase fusion pro-
teins). More likely, in vitro transcription/translation meth-
ods will be used, since only small amounts of proteins are
required. Several large, arrayed clone collections are avail-
able commercially. These could be employed as templates
for PCR using primers designed to incorporate a promoter
and an a⁄nity tag, thus producing the DNA substrate for
in vitro transcription (Fig. 3). Subsequent in vitro trans-
lation would then produce the tagged protein which could
be immobilized selectively at the appropriate spot on the
array by speci¢c binding to a capture agent. The simplest
example of this would be to epitope-tag the protein and
display the cognate monoclonal antibody on the slide.
Alternatively, a protocol has been developed to incorpo-
rate biotin co-translationally into a protein (Hayhearst et
al., personal communication; also see [15]). The least de-
sirable, but potentially workable, solution would be to
perform a quick, automated a⁄nity puri¢cation of the
tagged protein and then bind it covalently to a chip modi-
¢ed with lysine-reactive groups.
This is one reason that protein function arrays are much
simpler than protein-detecting arrays. It is obvious what
to spot down. The other is that for at least ¢rst-generation
applications of protein function chips, a single or a small
number of soluble analytes will be employed. These can be
labeled synthetically, allowing ready visualization of the
positions on the chip at which they bind. In the case of
protein-detecting arrays, it is not obvious what to spot
down and £uorescent labeling of the cell extract, blood
sample, etc. may not be an optimal approach to visualiz-
ing binding events. In summary, it seems likely that in the
near future, protein function arrays will become widely
available and will occupy an important place in the bat-
tery of techniques by which to analyze molecular interac-
tions on a genome-wide scale.
4. Protein-detecting arrays: the ligand problem
The ideal proteomics-based analytical tool would con-
sist of a microarray of a large number of high a⁄nity,
high speci¢city protein ligands, one for each protein in
the proteome of interest. For humans, this would mean
isolating in the order of 100 000 good monoclonal anti-
bodies or the equivalent (vide infra). In reality, the number
would be much higher, since the detection of di¡erent
post-translationally modi¢ed forms of a protein is one of
the principal advantages of moving from nucleic acid to
protein-based analytical techniques. Just to take a round
number, let us assume that 1 000 000 high a⁄nity ligands
would be needed to make the ideal protein-detecting mi-
croarray. Would anyone care to isolate that many mono-
clonal antibodies? Of course, the ¢eld will proceed in a
stepwise fashion and a reasonable intermediate goal would
be to construct arrays of 1000 protein-binding ligands di-
rected against proteins of interest in a particular disease
state, for example. Nonetheless, these numbers highlight
the ¢rst problem that must be solved to begin to seriously
develop protein-detecting microarrays: the rapid and e⁄-
cient isolation of high a⁄nity and speci¢city protein li-
gands. While the ¢rst protein-detecting chips will almost
certainly be based on monoclonal antibodies produced by
traditional means, these will largely be for show. It is
simply impractical in the long run to make many thou-
sands of monoclonal antibodies by standard protein prep-
aration/animal immunization/hybridoma techniques.
This is not to say that antibodies are not promising
Fig. 3. Diagram of a protocol that could be employed to make protein
function arrays comprised of thousands of immobilized proteins. PCR
would be employed to amplify the gene of interest from cDNA using
primers that would allow a T7 promoter to be incorporated 5P to the
gene and which would place sequences encoding an a⁄nity tag at the 3P
end. In vitro transcription/translation would provide the desired protein
containing the a⁄nity tag. The protein would then be immobilized by
spotting onto a glass slide impregnated with a molecule able to bind the
a⁄nity tag tightly. All other proteins in the translation mixture would
be washed away. Many tag/capture pairs can be imagined. The ¢gure
depicts a small epitope (red box) that is recognized by a monoclonal
antibody.
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binding agents for use in protein-detecting arrays (for ex-
ample, see [16]). On the contrary, they are currently the
only class of molecules generally able to serve as high
speci¢city, high a⁄nity ligands for almost any given pro-
tein. The challenge will be to devise alternative methods
for their isolation that are amenable to high-throughput
and scale-up. For example, libraries of single-chain anti-
bodies can be displayed on the surface of bacteriophage,
bacteria or yeast and these libraries can be panned for
molecules that bind to a given protein target [17^21].
There a number of important technical problems to be
addressed before high a⁄nity antibodies can be obtained
in a high-throughput fashion, but this route to recombi-
nant antibodies is likely to be a major player in the con-
struction of ¢rst-generation protein-detecting arrays.
Competing with recombinant antibodies will be various
antibody-like (in a functional, not structural, sense) mole-
cules that have been termed protein aptamers. These are
protein derivatives engineered to display peptide libraries.
Perhaps the best examples of such species are the thiore-
doxin-based aptamers developed by Brent et al. [22^24].
Thioredoxin is a small, very stable protein that contains a
surface loop that is highly tolerant of sequence variability.
At the nucleic acid level, a peptide library-encoding mixed
oligonucleotide library was inserted into the appropriate
position of the gene to create the aptamer library. This
was done in the context of a fusion to a transcriptional
activation domain. This allowed the library to be screened
by a modi¢ed two-hybrid method in yeast using a target
protein fused to a sequence-speci¢c DNA-binding domain.
Very good results have been reported using this system.
Aptamers capable of binding their targets with KDs in the
nM region were obtained in several cases.
Another possibility is nucleic acid aptamers, either
RNA or DNA [25]. Nucleic acid aptamers can be selected
in vitro based on repeated cycles of binding and PCR. A
major advantage of this class of molecules is that it is very
straightforward to carry out a⁄nity maturation in the pro-
cess of the selection, allowing very high a⁄nity ligands to
be obtained [26]. Given that they are highly negatively
charged molecules, it is likely that nucleic acid aptamers
will work well with targets containing positive charge
patches on their surface. How broad their applicability
will be in a proteome-wide sense remains to be deter-
mined.
Finally, one can consider small molecule ligands for
proteins. Since the term small molecule means di¡erent
things to chemists and biologists, I will de¢ne it to mean
a species that can be obtained readily by chemical syn-
thesis. In the long run, small molecule ligands have enor-
mous potential advantages over macromolecular protein
or nucleic acid ligands. They are generally far more ro-
bust. More importantly, one can carry out chemical syn-
thesis on large scales, thus making supply of the protein-
binding ligands much simpler if such technology were
scaled up to commercial levels.
It is now becoming commonplace to identify organic
compounds that bind proteins through combinatorial li-
brary methods. In general, a library is made by solid-phase
synthesis using split/pool methodology and, if necessary,
encoded tags are included in the synthetic scheme. The
collection of beads is then mixed with a labeled protein
derivative and the beads which bind the protein of interest
are identi¢ed. Usually, this process is carried out with a
single protein target, but there is no reason why it could
not be made more parallel by employing many targets at
once. Fig. 4 depicts a scheme that represents the limit of
this sort of approach. One could take a cDNA library
designed to express a fusion of the proteins of interest to
green £uorescent protein (GFP), horseradish peroxidase
(HRP) or some other easily detectable molecule and trans-
form this library into E. coli. Rather than segregating the
resultant transformants, all of the bacteria would be
grown up together and a mixed extract would be made
containing all of the GFP fusion proteins (or at least all
of those that express well in soluble form). This mixture
could then be incubated with a library of bead-bound
chemicals. After the appropriate washing steps, any beads
that light up would be collected, resulting in the isolation
of all compounds in the library that have a reasonable
a⁄nity for some protein in the proteome of interest.
Which compound binds which target would then have to
be deconvoluted. This might be as straightforward as sam-
pling the fusion protein bound to each bead by MS.
It seems likely that some strategy akin to that shown in
Fig. 4 will be capable of providing a wealth of lead com-
pounds. The real challenge in developing small molecule-
based protein-detecting arrays is in isolating ligands with
high a⁄nity. It has been our experience, working with
Fig. 4. A scheme for screening chemical libraries against many protein
targets simultaneously. A library containing many labeled proteins (in
the case GFP fusions) is expressed and the mixture incubated with a
bead-bound chemical library constructed by split/pool synthesis. After
washing, the beads that remain £uorescent are collected and scored as
possible protein ligands. Some scheme would be required to deconvolute
which protein bound to any particular bead. This might be done by di-
rect MS analysis of the material on the bead. The library would have
been pre-screened with GFP lacking a cDNA-encoded fusion. Any
GFP-binding beads would be removed prior to the experiment.
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peptide libraries, that the best ligands one isolates in such
screens bind their targets with KDs in the order of 1036 to
1037 M [27,28]. While these modest a⁄nities may be suit-
able for some applications, one would ideally like to have
ligands that bind their target with the a⁄nity of a good
antibody (KD in the 1039 to 10312 M range). In general, it
seems clear that the lead molecules will have to be elabo-
rated signi¢cantly to achieve large jumps in a⁄nity. It is
unlikely that methyl/ethyl/propyl-level tinkering will
achieve this goal and traditional SAR/a⁄nity maturation
approaches are much too tedious in any case. One prom-
ising approach is to link together two low a⁄nity ligands
that bind di¡erent surfaces of a given target, but current
methods [29,30] to execute this strategy will have to be re-
engineered to accommodate a much higher throughput.
This is certainly an area where a creative chemical biolo-
gist could have an enormous impact. One advantage here
relative to the somewhat analogous development of a drug
from a lead compound is that the molecular mass, cell
permeability and other pharmacokinetic properties of the
protein ligand are irrelevant as long as large quantities can
be made easily at the end of the day.
5. Protein-detecting arrays: the detection problem
As di⁄cult as it is going to be to isolate and produce
thousands of high a⁄nity and speci¢city protein ligands, it
may be even harder to come up with a good way to mon-
itor binding of proteins to the chip. Thinking in this area
is dominated by analogies to DNA microarrays, which
may not be very useful. As mentioned above, the cDNAs
that are actually detected in an expression analysis experi-
ment are £uorescently labeled during the reverse transcrip-
tion step. Obviously, the analogous protocol cannot be
used to label a protein, but it is generally assumed that
one could £uorescently label proteins chemically. For ex-
ample, one could take a cell extract and treat it with a
commercially available N-hydroxysuccinimide ester of car-
boxy£uorescein or some similar compound to derivatize
the terminal amine of lysines that are commonly on the
surface of most proteins. This sample would then be in-
cubated with the chip and the retained £uorescent proteins
would be detected with a simple reader as is now done in
the DNA microarray ¢eld.
There are several problems with this approach, though
it will probably be the one adopted in the early days of
protein-detecting microarrays. First, the chemical hetero-
geneity of proteins makes this hopeless as a strategy for
doing quantitative work. Some proteins will label far more
e⁄ciently than others. The absolute intensity observed on
a particular spot on a chip would be meaningless in the
absence of a calibration curve determined using well-char-
acterized standards. Again, the scale involved defeats the
idea of generating calibration curves for every protein^li-
gand complex. However, it should be pointed out that
even in the DNA microarray area, absolute quantitation
is di⁄cult and most experiments focus on discerning dif-
ferences between two samples. Most protein-detecting ar-
rays will likely be employed in the same way (see Fig. 1,
bottom). For example, extracts made from wild-type yeast
and a congenic deletion mutant would be treated with two
di¡erent colored dyes. The extracts would be mixed, then
incubated with the protein-detecting array. The ratios of
colors that bind to each spot on the array would be re-
corded, in direct analogy to DNA microarray methodol-
ogy, providing a relative measurement of the change in
expression level of the various proteins. In theory at least,
this would render the di¡erence in the chemical e⁄ciency
of £uorescence labeling of various proteins unimportant.
With relative abundance experiments in mind then, the
real problem with chemical labeling of proteins is that it
changes their surface characteristics greatly. In particular,
reactions that convert positively charged lysine side chains
to amides could result in signi¢cant protein denaturation.
Even more troubling is that the £uorescently labeled pro-
tein may no longer bind to the immobilized ligand, which
was selected against the native protein. This will be an
especially large concern with smaller proteins and peptide
hormones. It remains to be seen how pervasive a problem
this will be, but chemical labeling of the protein sample is
clearly not the optimal solution for the visualization of
binding events. Even if the above concerns prove to be
overstated, chemical derivatization represents an un-
wanted and labor-intensive processing step that would
make the high volume use of protein-detecting arrays
more problematic.
A major opportunity in this area in to devise a solution
to the detection problem that does not require sample
labeling. In general, the most appealing solution would
be to modify the capture ligands with some sort of sensi-
tive reporter that would record the analyte protein-ligand
binding event. There are many possibilities, but perhaps
the most appealing would be to attach the capture ligands
to materials that can change their emission or conductive
properties signi¢cantly in response to a binding event. This
would provide an intrinsically responsive surface. An al-
ternative would be to modify the capture ligands with a
reporter capable of signaling binding of the target of the
macromolecule with high sensitivity.
Another general type of approach would be to employ a
sandwich assay of some sort (Fig. 5) in which the analyte
protein of interest is bound by both the immobilized cap-
ture ligand and a soluble sandwich ligand. The latter
would be equipped with some reporter that is easily de-
tectable. The labeled sandwich ligand would adhere to the
chip only if the protein analyte was bound. An advantage
of a sandwich approach is that the sandwich ligand could
be conjugated to an enzyme (Fig. 5), thus allowing signi¢-
cant ampli¢cation of the binding signal. This will be very
important for the detection of low level proteins, hor-
mones, cytokines, etc. The obvious downside to this oth-
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erwise appealing scheme is that two, rather than one, li-
gands are required for each protein. This would not be so
bad except that one must know that the capture and sand-
wich ligands do not compete for the target protein. This
means that either competition binding experiments would
have to be conducted with ligands isolated in an initial
screen, or that a second screen would have to be con-
ducted for ligands that bind the protein of interest in the
presence of saturating amounts of the initially selected li-
gand. In either case, this further complicates an already
daunting ligand isolation problem.
There are some existing protein analytical techniques
with enough sensitivity to detect binding of proteins to
the immobilized ligands directly without the requirement
of labeling or ampli¢cation. The most obvious is MS. For
example, one can imagine immersing a protein-detecting
array in an appropriate matrix, then sampling each spot
on the array by matrix-assisted laser desorption-ionization
time-of-£ight MS. The Achilles heel of MS is that it is
di⁄cult to quantitate signals, so it would be challenging
to compare the intensities of the protein signals from cor-
responding spots on two di¡erent chips. Of course, one
cannot mix two di¡erent samples and apply them to a
single chip, since the signals from the same protein in
the two samples will be indistinguishable. To address
this problem, Aebersold et al. have recently reported an
isotope labeling technique that is somewhat analogous to
the idea of two-color labeling, but employs isotope tags
rather than £uorescent dyes [31]. A reduced sample is
treated with a sulfhydryl-reactive, biotin-containing agent.
The proteins are then proteolyzed and the derivatized,
cysteine-containing peptides are collected by avidin a⁄nity
chromatography and identi¢ed by high performance liquid
chromatography-coupled MS/MS. The trick here is to
treat one of the two samples to be compared with a D8-
derivative of the cysteine-reactive compound. This pro-
vides an isotopic label that allows peptide from one sam-
ple to be compared quantitatively to the analogous species
obtained from the other sample. This technique has many
of the same drawbacks as £uorescent protein labeling and
is not readily applicable to the format of a protein-detect-
ing array. However, I bring it up to suggest that if some
clever technique could be devised by which one could iso-
topically label proteins in vivo, then direct MS analysis of
proteins from two samples bound to the chip could be
carried out quantitatively.
Finally, binding events could be determined by surface
plasmon resonance (SPR) [32]. While technically incorrect
(I will spare the reader a digression into the physics of
plasmon resonance), it is pedagogically useful to think of
an SPR instrument (better known to many biochemists as
a BIAcore) as a highly sensitive microbalance in which a
laser interrogates the backside of a chemically modi¢ed
gold chip and records changes in the mass of the immo-
bilized complex. SPR is a very sensitive technique and
appears quite attractive for this application. The technical
hurdle here is that an SPR instrument would have to be
made that is capable of analyzing thousands of spots in a
relatively short period of time. While I am not an engi-
neer, it seems reasonable that such an instrument could be
constructed by allowing the laser to move from feature to
feature (or more probably moving the multi-feature chip
with respect to a stationary laser). Ironically, the issue that
will probably prove most problematic for the development
of SPR-based protein-detecting arrays is that it may be
di⁄cult to carry out relative measurements of protein sam-
ples on the same array, which is what most users will want
to do. Since SPR essentially responds to mass changes,
there is no obvious analogue of a two-color label or iso-
topic labeling scheme that could be applied here. There-
fore, one will likely have to attempt to contrast absolute
signals obtained from two di¡erent spots, which has its
own problems, including complications due to protein^
protein interactions (see Section 6). Nonetheless, in the
medium to long term, SPR is a promising technology in
the protein array area, particularly when the ¢eld eventu-
ally turns to intrinsic quantitative measurements.
6. The complications of protein^protein interactions
As mentioned above, much of the thinking in the pro-
tein array area has been dominated by analogies with
DNA microarrays. A particularly misleading facet of
this mindset is that it leads workers in the ¢eld to ignore
the consequences of the fact that proteins tend to associate
Fig. 5. Schematic view of a sandwich assay for detecting binding of the
target protein (orange) to the immobilized ligand (blue). A second pro-
tein-binding agent (pink) would be isolated that does not compete with
the immobilized capture ligand. The latter molecule would be fused to
HRP (in red) or some other reporter enzyme that would allow ampli¢-
cation and visualization of the binding event. This sort of detection
strategy would not require chemical labeling of the protein sample.
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with one another. Indeed, it is now generally appreciated
that most biological events are mediated by ‘protein ma-
chines’ [33] comprised of anywhere from several to almost
100 di¡erent polypeptides. This leads to a complication in
the design of ligand discovery strategies that I believe is
grossly underappreciated.
To obtain protein ligands, virtually everyone involved in
this ¢eld plans to screen some sort of library (comprised of
antibodies, peptides, nucleic acid or protein aptamers, or
small molecules) against recombinant proteins or protein
domains. However, the experience of several laboratories
[34,35], including my own [28], is that the ligands obtained
in such screens almost invariably bind to native interaction
regions of the target protein. This is presumably because
sites of native protein^protein interactions are the most
‘bindable’ regions of the protein. In other words, other
surfaces of the protein have probably evolved to prevent
non-speci¢c interactions with other factors in the very
concentrated milieu of the cell.
This has interesting consequences with regard to em-
ploying the isolated compounds as ligands for protein-de-
tecting arrays. At least in experiments using cell extracts
prepared under more or less physiological conditions, it
seems likely that a majority of the ligands on the chip
will have to compete with native factors for binding of
the target protein. Depending on the relative a⁄nities of
the immobilized ligand and the native competitor protein
for the target factor and several other factors (see below),
this competition will result in only some fraction of the
target protein in the extract binding to the chip (Fig. 6).
Since the a⁄nities of native protein^protein interactions
can vary over several orders of magnitude, this means
that the absolute amount of protein that binds to a spot
on the array may diverge wildly from its true concentra-
tion in the sample. Some proteins may not bind at all if
the ligand-binding site is occluded in the interior of a
stable complex. This is one of many problems inherent
in absolute measurements using this technology. The sit-
uation is analogous to one with which molecular biologists
are quite familiar. If one isolates an antibody against a
given protein, even if it performs well in a Western blot
experiment where protein complexes have been disrupted,
it may or may not be useful in an immunoprecipitation
application. It all depends on the accessibility of the epi-
tope recognized by the antibody.
The complicating e¡ects of protein^protein interactions
are ameliorated to some extent if one attempts only rela-
tive measurements between two samples. In other words,
one would hope that the intrinsic ‘partition ratio’ between
a target peptide binding to the immobilized ligand and the
native competitor protein would be a constant one, there-
fore allowing comparative measurements between two dif-
ferent samples to be made. Unfortunately, this will not
always be true. For instance, consider a case in which a
change in the physiological state of the cell reduces the
amount of competitor protein Y, which binds target pro-
tein X. Presumably, this would result in a signi¢cant in-
crease in the amount of protein X bound to the appropri-
ate spot on the array. Thus, it would be easy to
misinterpret the data as indicative of that physiological
stimulus resulting in a signi¢cant increase in the level of
protein X. Of course, if one had an array that monitored
every protein in the proteome, one might be able to de-
convolute all of the data appropriately. But an array of
Fig. 6. The e¡ect of protein^protein interactions on protein binding to
immobilized capture ligands. This ¢gure represents two multi-protein
complexes, each containing a protein (orange) for which a speci¢c li-
gand is present in the array (blue). The illustrations represent cases in
which one protein is bound tightly in the complex, the other loosely. If
the capture ligand must compete with the other proteins in the complex
for the target factor, then the di¡erent a⁄nities of the targets for their
natural partners will result in di¡erent amounts of that factor being cap-
tured on the array. This simple analysis does not take into account the
fact that the capture ligand^target protein a⁄nities will undoubtedly
also be di¡erent. Factors such as these will make absolute quantitation
of protein levels using array technology extremely di⁄cult. However,
while other complications remain (see text), measurements of relative
changes between two samples (Fig. 1, bottom) will be less troubled by
such e¡ects.
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this complexity will not be available for some time and
even then, such corrections would require an extensive
knowledge of the network of protein^protein interactions
in the proteome of interest and a complex bioinformatics
approach to signal correction. Finally, the same problem
could arise even if the level of protein Y does not change
drastically. For example, suppose a change in conditions
results in phosphorylation of protein Y and that this event
drastically reduces its a⁄nity for protein X.
The issue of protein^protein interactions provides spe-
cial challenges to the development of SPR as a detection
technique. Whether protein X binds to a given spot on a
chip as a free polypeptide or as one of dozens of proteins
in a stable complex will obviously provide grossly di¡erent
signal intensities (Fig. 7). This is an advantage of MS over
SPR as the most desirable ‘direct analysis’ tool for protein
arrays, since MS will segregate all of the di¡erent proteins
in the complex, allowing only the signal of protein X to be
analyzed. There has been interest in coupling SPR with
MS [36] and if the advantages of both techniques could
be exploited, this might be a promising approach to de-
tection.
A ¢nal point relevant to this topic is that it might be
possible to avoid the problem if one could somehow de-
mand that the ligand bind the target protein in a region
that does not participate in native interactions. This will
not be easy, but it may be possible. The simplest approach
would be to employ as targets in the library screening
experiments suitable peptide epitopes derived from the
target protein rather than the intact protein itself. These
epitopes would be selected based on structural knowledge
or (more often) on bioinformatics-based guesses as to
what regions of the protein are not likely to be involved
in intermolecular interactions. Unfortunately, this ap-
proach will complicate ligand isolation, since it is going
to be more di⁄cult to obtain compounds that bind peptide
epitopes than those that snuggle into the molecular crevi-
ces and caverns available in a folded protein. This is par-
ticularly true if one is talking about small molecule li-
gands. While one can imagine selecting monoclonal
antibodies that bind peptide epitopes in a high-throughput
fashion, the literature on epitope-binding small molecules
is extremely slim. Indeed, to the best of my knowledge,
there have only been two reports of screening libraries for
chemically synthesizable molecules capable of binding pep-
tide epitopes in aqueous solution, both involving epitope-
binding peptides [37,38]. It will be interesting to see how
this very nascent ¢eld develops over the next few years.
In summary, it is safe to say that the extensive networks
of protein^protein interactions present in the cell will pro-
vide a considerable challenge to interpreting the data ob-
tained from protein-detecting microarrays correctly. To be
fair, it should be pointed out that this issue can probably
be put o¡ for a while, since there are applications for
which it will not be a major issue. For instance, protein^
protein interactions will be much less prevalent in blood
samples than in cell extracts. Also, if one is looking for
nothing more than a biosignature indicative of a disease
state or a pathogen infection, then interpretation of the
signal intensities is irrelevant. So clearly, this issue should
not paralyze advances in the ¢eld. Almost every new tech-
nology has recognized pitfalls that are ignored in the ¢rst
wave of development. However, for the core application of
using protein-detecting arrays as a central tool in biolog-
ical research, where cell extracts will likely be the most
common sample, dealing with the impact of protein^pro-
tein interactions is an important problem that will even-
tually require considerable e¡ort and imagination to solve.
7. Ligands speci¢c for a particular form of a protein
As discussed in Section 1, one of the most powerful
arguments for the development of protein-detecting arrays
is that DNA microarrays are blind to chemical alterations
in the state of the protein that can have tremendous e¡ects
on its function. I used the term post-translational modi¢-
cation previously and, indeed, covalent modi¢cation of
protein side chains or cleavage of main chains is one of
the dominant mechanisms by which protein activity is
regulated. However, it is important to point out that
non-covalent events also can have important consequences
on protein function. For example, the activity of Ras
bound to GTP is very di¡erent than that of Ras com-
Fig. 7. Capture ligands that bind a surface of the target protein not oc-
cluded in native complexes (left) would not su¡er from complications
due to competing with native protein^protein interactions (right). How-
ever, since selection experiments using intact proteins or protein do-
mains generally provide compounds that recognize native interaction
surfaces, obtaining ligands such as that shown on the left may require
using speci¢c epitopes as targets in library screens. If SPR were em-
ployed to monitor binding, these two types of binding events would
provide dramatically di¡erent responses. For this technique to be of
use, therefore, one would have to know whether the capture ligand
binds the target protein in isolation or as part of a complex. This is a
signi¢cant obstacle to the implementation of SPR as an array analysis
technique even if instruments capable of multiple measurements become
available.
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plexed to GDP. In general, therefore, one would ideally
like to have ligands capable of distinguishing between dif-
ferent molecular states of a given protein in order to take
full advantage of the potential of protein-detecting arrays.
This provides yet another challenge in the ligand screen-
ing area. The most straightforward approach would be to
employ as a target in any given library screening experi-
ment the desired form of the protein, for example phos-
phorylated at a given serine. But there is no guarantee that
the ligands obtained in such an experiment would be spe-
ci¢c for that form of the protein. Thus, some kind of
rescreening against the unmodi¢ed form of the factor
would be required. This may not sound so bad, but
when extremely high-throughput is required, schemes re-
quiring multiple subsequent steps after the initial screening
event become cumbersome. Furthermore, there is no guar-
antee that any of the selected ligands will be speci¢c for
the desired form of the protein. Finally, in many cases it
may be di⁄cult to prepare in pure form the desired post-
translationally modi¢ed version of the target protein. This
is particularly true for phosphorylated proteins, where the
kinase that operates on them is often unknown or not
readily available.
One possible solution to this problem is to focus on
epitopes as targets. If a 10^15 amino acid epitope contain-
ing a phosphorylated serine, for example, were employed
as the target in a library screening experiment, it seems far
more likely that the ligands isolated would distinguish
between the phosphorylated or unphosphorylated forms.
In addition, a phosphorylated peptide could be made syn-
thetically, simplifying target preparation. Particularly in
the case where phage-displayed single chain antibody li-
braries are employed as the source of protein-binding li-
gands, this may be the most e¡ective strategy to obtain
ligands with the desired speci¢city. To obtain relatively
small molecules capable of distinguishing di¡erent forms
of an epitope will be far more challenging.
8. Conclusion
Protein arrays will likely be the next major manifesta-
tion of the revolution in genomics and proteomics. An
important distinction in this area is to recognize that
two fundamentally di¡erent types of arrays will be devel-
oped. Protein function arrays, which will almost certainly
come into general use ¢rst, will be comprised of native
proteins arrayed on chips. These arrays will be extremely
useful for studies of the activities and binding properties of
native proteins and will also be of broad utility in address-
ing the speci¢city of protein-binding small molecules, in-
cluding drug candidates. The second type of chip, which I
have termed a protein-detecting array, will be used to
monitor the levels and chemical states of native proteins.
These arrays will be the proteomics version of DNA mi-
croarrays and will be utilized for proteome-wide pro¢ling
experiments. There are two major technical hurdles that
must be addressed before relatively sophisticated protein-
detecting arrays can be produced. One is the development
of high-throughput technology for the isolation of high
speci¢city and a⁄nity protein ligands. The other is to de-
vise a robust method to detect binding of the proteins in a
biological sample to the array, preferably without the need
to chemically modify the protein analytes. Once these is-
sues are solved, there will remain a variety of interesting
secondary challenges, including the development of meth-
ods to distinguish between di¡erent forms of the same
protein and strategies to deal with the complications im-
posed by native protein^protein interactions. Therefore, it
is safe to say that this will continue to be an interesting
area in need of innovative thinking for several years.
It is di⁄cult to overstate the importance of the develop-
ment of practical devices of this sort. It would not be
surprising if in 10^20 years time protein-detecting arrays
form the backbone of medical diagnostics. This is an area
of tremendous opportunity for biologically inclined organ-
ic chemists, particularly those with a strong background in
physical chemistry and engineering (or with good collab-
orators in these areas). In particular, while the ¢rst gen-
eration protein-detecting chips will rely almost exclusively
on antibodies or other macromolecules, there are many
practical problems associated with making complex chips
from these materials, particularly for mass production. It
is my opinion that the full potential of this technology will
be realized only when ligands that can be synthesized
chemically become available for thousands of proteins.
Indeed, while I have discussed the problems of ligand iso-
lation and detection of binding as being more or less in-
dependent, this may not be the case. One can certainly
imagine tailoring the ligands themselves to somehow aid
in reporting when they bind their target protein. In con-
sidering such approaches, there is no substitute for the
£exibility a¡orded by synthetic chemistry. Clearly, this is
a problem made to order for chemical biologists. Indeed,
it can be argued that the ‘protein binding problem’ is the
ultimate challenge in molecular recognition today and one
worthy of the attention of the best people in the ¢eld.
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